Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bristol Sweetens ImClone Bid A Bit, Plans To Ask Stockholders To Replace Board

This article was originally published in The Pink Sheet Daily

Executive Summary

BMS ups ante by $2 per share, for a total $4.7 billion cash offer.

You may also be interested in...



Lilly’s ImClone Buy Adds Oncology Candidates And Pipeline Pressures

Eli Lilly announced Oct. 6 that it is acquiring ImClone for $6.5 billion, confirming rumors that had been circulating since the middle of the previous week. The central question now is whether Lilly can turn the buyout into a win for shareholders

Lilly’s ImClone Buy Adds Oncology Candidates And Pipeline Pressures

Eli Lilly announced Oct. 6 that it is acquiring ImClone for $6.5 billion, confirming rumors that had been circulating since the middle of the previous week. The central question now is whether Lilly can turn the buyout into a win for shareholders

Lilly Snatches ImClone Away From Bristol

Lilly’s $6.5 billion acquisition of ImClone will create an oncology “powerhouse” with 18 cancer drugs in clinical development.

Related Content

Topics

UsernamePublicRestriction

Register

OM003387

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel